CAMBRIDGE, Mass., August 10, 2021 – Today, DoubleRainbow Biosciences, a sustainable health care company harnessing the power of natural evolution through bioengineering to improve the quality of human health, announced a new $10 million investment from Betta Pharmaceuticals as part of the organization’s Series B funding round. The company has raised $26 million to date, with plans to use financing to accelerate compounds into clinical development, grow the organization’s bioceutical division, and expand critical R&D and clinical operations teams.

​“Our proprietary platforms allow us to access nature’s astonishing array of therapeutic compounds to bring novel therapeutics and bioceuticals to the world at scale without harming the environment,” said Jing-Ke Weng, Ph.D., Co-founder of Double Rainbow.

Double Rainbow was founded in 2017, and features a team of leading experts from across academia and the biophar­ma­ceu­tical industry. The company has quickly developed a robust pipeline of early-stage assets spanning its enzyme modification and molecular biosynthesis platforms. Through the support of Betta Pharmaceuticals and other investors, Double Rainbow is poised to accelerate its first therapeutic compound to clinical development, while also preparing to launch the company’s first bioceutical product.

“We are working tirelessly to harness the power of natural biology and biochemistry to explore areas of significant unmet medical need like oncology, neurological diseases, and metabolic disorders,” said Holly Schachner, M.D., Chief Medical Officer of Double Rainbow. ​“This latest investment will enable us to progress our promising early-stage pipeline to clinical development, with the ultimate goal of delivering unique and novel treatments to patients around the world.”

About Double Rainbow

Double Rainbow is a sustainable health care company harnessing the power of natural evolution through bioengineering to improve the quality of human health and ensure the sustainability of our planet. By leveraging advances in the areas of genomics, metabolomics, and synthetic biology we are accessing the richness and efficacy of natural chemistry like never before, to bring therapeutics and bioceuticals to the world at scale without harming the environment. Learn more at www.doublerainbowbio.com.

Media Contact:
Grant Smith
Director, Corporate Communications & Strategic Marketing
317 – 518-9807
grant.smith@doublerainbowbio.com